【】 Objective: To explore the feasibility and influencing factors of constructing a patient derived tumor tissue xenograft model (PDX) in female reproductive system mice. Method: A mouse PDX model was constructed and passaged by collecting 78 patients suffering from gynecological oncology who treated in our hospital from March 2023 to October 2023, observations were made in June 2024. Result: ① Among the 37 mouse PDX models with clear outcomes, 7 cases (18.92%) were successfully modeled (passaged), and 22 cases (59.46%) were successfully implanted. Three cases of rare gynecological tumors were not successfully implanted. The success rate of implantation in P0 generation mice showed no significant difference between nude mice and NTG mice. There were no significant differences in tumor stage, tumor type and differentiation between the failed group and the successful inoculation group (p>0.05). ② 19 patients with cervical cancer had a modeling success rate of 15.8% (3/19), a total implantation success rate of 63.2% (12/19). The construction time for P0 generation varies from 25 to 87 (47 ± 16.7) days; The P1 generation is 55 days old; P2 generation takes 69 days. ③ 10 cases of endometrial cancer, the total implantation success rate is 60.0% (6/10),the success rate of modeling is 10.0% (1/10). The construction time required for P0 generation is 24-93 (50 ± 19.7) days; P1 generation all takes 55 days; P2 generation for 41 days; P3 generation takes 55 days. ④ There were 5 cases of ovarian cancer, the total implantation success rate is 80.0% (4/5),the success rate of modeling is 60.0% (3/5). The construction time required for P0 generation is 30-75 (50 ± 20.7) days; P1 generation takes 68-125 (88 ± 32.1) days. ⑤ Among the 12 cases of cervical cancer successfully implanted in the model, 3 patients (75% success rate) who underwent neoadjuvant chemotherapy (NACT) and 1 case was implanted with metastases. Among the 4 cases of ovarian cancer successfully implanted in the model, 1 cases (50% success rate) were implanted with metastases. Therefore, mouse PDX models could be constructed after neoadjuvant chemotherapy and metastases of female reproductive system tumors. Conclusion: It is feasible to construct a mouse PDX model for female reproductive system tumors, and it is also feasible for tumor construction after chemotherapy or at the site of metastasis.